A detailed history of Citigroup Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Citigroup Inc holds 224,858 shares of ALKS stock, worth $6.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
224,858
Previous 159,322 41.13%
Holding current value
$6.68 Million
Previous $3.84 Million 63.92%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.01 - $28.55 $1.51 Million - $1.87 Million
65,536 Added 41.13%
224,858 $6.29 Million
Q2 2024

Aug 12, 2024

SELL
$23.21 - $27.24 $5.71 Million - $6.7 Million
-246,083 Reduced 60.7%
159,322 $3.84 Million
Q1 2024

May 10, 2024

BUY
$26.4 - $32.56 $3.98 Million - $4.91 Million
150,729 Added 59.18%
405,405 $11 Million
Q4 2023

Feb 09, 2024

BUY
$23.37 - $28.68 $1.45 Million - $1.78 Million
62,020 Added 32.19%
254,676 $7.06 Million
Q3 2023

Nov 09, 2023

BUY
$27.17 - $31.97 $540,981 - $636,554
19,911 Added 11.53%
192,656 $5.4 Million
Q2 2023

Aug 10, 2023

SELL
$28.34 - $33.63 $1.5 Million - $1.78 Million
-52,781 Reduced 23.4%
172,745 $5.41 Million
Q1 2023

May 11, 2023

BUY
$25.31 - $29.02 $1.57 Million - $1.8 Million
62,056 Added 37.96%
225,526 $6.36 Million
Q4 2022

Feb 09, 2023

SELL
$21.94 - $26.24 $2.98 Million - $3.57 Million
-135,895 Reduced 45.39%
163,470 $4.27 Million
Q3 2022

Nov 10, 2022

SELL
$22.0 - $31.87 $231,264 - $335,017
-10,512 Reduced 3.39%
299,365 $6.68 Million
Q2 2022

Aug 10, 2022

BUY
$26.4 - $30.54 $5.09 Million - $5.89 Million
192,915 Added 164.94%
309,877 $9.23 Million
Q1 2022

May 12, 2022

SELL
$23.07 - $27.99 $2.96 Million - $3.59 Million
-128,093 Reduced 52.27%
116,962 $3.08 Million
Q4 2021

Feb 10, 2022

BUY
$21.47 - $32.08 $1.34 Million - $2.01 Million
62,634 Added 34.33%
245,055 $5.7 Million
Q3 2021

Nov 10, 2021

BUY
$23.37 - $32.13 $4.26 Million - $5.86 Million
182,421 New
182,421 $5.63 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.88B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.